STAT News

STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent

Investors and doctors are intensely awaiting mid-stage results of an experimental Kymera therapy positioned to rival Dupixent.

By STAT News

1 min read
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights